menu

My Patient's At 'Low Risk' for Clinically Significant Fibrosis: What Should I Do Now?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes 

My Patient's At 'Low Risk' for Clinically Significant Fibrosis: What Should I Do Now?

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    This series of bite-sized episodes will provide important information on MASLD and MASH in patients with type 2 diabetes. Drs. Naim Alkhouri and Robert Eckel and physician assistant Tessa Janovsky discuss best practices for screening, diagnosis, treatment, and management of MASH/MASLD.   

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Naim Alkhouri, MD, FAASLD
    Chief Medical Officer
    Chief of Transplant Hepatology
    Director of the Fatty Liver Program
    Arizona Liver Health
    Phoenix, AZ

    Dr. Naim Alkhouri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: 89Bio, Akero, Arbutus, AstraZeneka, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Corcept, Cymabay, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus. 
    Consulting Fees: 89Bio, AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.

    Faculty:
    Robert Eckel, MD, FAHA, FACC, FNLA
    Professor of Physiology and Biophysics
    Charles A. Boettcher Endowed Chair in Atherosclerosis
    University of Colorado Anschutz Medical Campus   
    Aurora, CO 

    Dr. Eckel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Ionis, Novo Nordisk, and Arrowhead

    Tessa Janovsky, PA-C
    Physician Assistant, Hepatology
    Arizona Liver Health
    Phoenix, AZ

    Ms. Janovsky has reported no relevant financial relationships or relationship with ineligible companies of any amount during the past 24 months. 

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose. 
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MAhas nothing to disclose.
    • Haemin Go has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
    • Brad Bongiovanni, ND
    • Vin Kalathiveetil has nothing to disclose.
    • Colleen Resnick has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Show how to determine which adults should be screened for clinically significant fibrosis.
    • Interpret a FIB-4 score to determine a patient's risk for comorbid liver disease with clinically significant fibrosis.
    • Determine the most appropriate next step in a patient with risk factors for MASLD/MASH and a given fibrosis risk score.
    • Select the most appropriate treatment for a patient with a cardiometabolic condition and MASLD/MASH.
  • Target Audience

    This activity has been designed to meet the educational needs of endocrinologists and primary care physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and all other healthcare providers involved in managing patients with Type 2 Diabetes.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this MinuteCE  activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until June 13, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.  


    Global Learning Collaborative (GLC) designates this activity for 1 contact hours/.1 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-062-H01-P. This learning activity is -based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)


    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

     

  • Commercial Support

    This activity is supported by an independent educational grant from Novo Nordisk, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Jul 2024